“A majority of cases of ophthalmologic involvement as a reported side effect improved after initiation of appropriate therapy by ophthalmology,” the authors write.
Real-world results suggest dupilumab is an excellent treatment modality for moderate-to-severe atopic dermatitis, as it is effective and better tolerated than other immunomodulators used in patients with atopic dermatitis, Drs. Grando, professor of dermatology and biological chemistry, and Kraus, resident physician in dermatology at University of California, Irvine, write.
“Overall, what we can conclude from our study is that the majority of patients do very well on this medication,” they write. “Of the eleven patients that did not improve while on dupilumab, ten had been on the medication for less than 16 weeks (and one was misdiagnosed). While many of our patients experienced clinical improvement rapidly, these findings suggest there may be a subset of patients that require a longer duration of initial treatment prior to responding and thus, the medication may have been discontinued too soon to adequately assess response. The patients with the most severe cases of atopic dermatitis had the longest delay in achieving therapeutic effect.”
The remaining symptoms can be safely managed by co-administration of various topical agents, anti-histamines, systemic steroids or light therapy, according to Drs. Grando and Kraus.
1. Wang C, Kraus CN, Patel KG, Ganesan AK, Grando SA. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records. Int J Dermatol. 2019;
2. Ruiz-villaverde R, Dominguez-cruz J, Armario-hita JC, Martinez-pilar L, Alcantara-luna S, Pereyra-rodriguez JJ. Dupilumab: short-term effectiveness and security in real clinical practice - A retrospective multicentric study. J Eur Acad Dermatol Venereol. 2019;33(1):e21-e22.
3. Faiz S, Giovannelli J, Podevin C, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019;81(1):143-151.